247 related articles for article (PubMed ID: 34884967)
1. Dystroglycanopathy: From Elucidation of Molecular and Pathological Mechanisms to Development of Treatment Methods.
Kanagawa M
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884967
[TBL] [Abstract][Full Text] [Related]
2. Muscular Dystrophy with Ribitol-Phosphate Deficiency: A Novel Post-Translational Mechanism in Dystroglycanopathy.
Kanagawa M; Toda T
J Neuromuscul Dis; 2017; 4(4):259-267. PubMed ID: 29081423
[TBL] [Abstract][Full Text] [Related]
3. Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy.
Kanagawa M; Nishimoto A; Chiyonobu T; Takeda S; Miyagoe-Suzuki Y; Wang F; Fujikake N; Taniguchi M; Lu Z; Tachikawa M; Nagai Y; Tashiro F; Miyazaki J; Tajima Y; Takeda S; Endo T; Kobayashi K; Campbell KP; Toda T
Hum Mol Genet; 2009 Feb; 18(4):621-31. PubMed ID: 19017726
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic aspects of the formation of α-dystroglycan and therapeutic research for the treatment of α-dystroglycanopathy: A review.
Taniguchi-Ikeda M; Morioka I; Iijima K; Toda T
Mol Aspects Med; 2016 Oct; 51():115-24. PubMed ID: 27421908
[TBL] [Abstract][Full Text] [Related]
5. Muscular dystrophies due to glycosylation defects: diagnosis and therapeutic strategies.
Muntoni F; Torelli S; Wells DJ; Brown SC
Curr Opin Neurol; 2011 Oct; 24(5):437-42. PubMed ID: 21825985
[TBL] [Abstract][Full Text] [Related]
6. Temporal requirement of dystroglycan glycosylation during brain development and rescue of severe cortical dysplasia via gene delivery in the fetal stage.
Sudo A; Kanagawa M; Kondo M; Ito C; Kobayashi K; Endo M; Minami Y; Aiba A; Toda T
Hum Mol Genet; 2018 Apr; 27(7):1174-1185. PubMed ID: 29360985
[TBL] [Abstract][Full Text] [Related]
7. Impaired viability of muscle precursor cells in muscular dystrophy with glycosylation defects and amelioration of its severe phenotype by limited gene expression.
Kanagawa M; Yu CC; Ito C; Fukada S; Hozoji-Inada M; Chiyo T; Kuga A; Matsuo M; Sato K; Yamaguchi M; Ito T; Ohtsuka Y; Katanosaka Y; Miyagoe-Suzuki Y; Naruse K; Kobayashi K; Okada T; Takeda S; Toda T
Hum Mol Genet; 2013 Aug; 22(15):3003-15. PubMed ID: 23562821
[TBL] [Abstract][Full Text] [Related]
8. Glycosylation with ribitol-phosphate in mammals: New insights into the O-mannosyl glycan.
Manya H; Endo T
Biochim Biophys Acta Gen Subj; 2017 Oct; 1861(10):2462-2472. PubMed ID: 28711406
[TBL] [Abstract][Full Text] [Related]
9. Mouse fukutin deletion impairs dystroglycan processing and recapitulates muscular dystrophy.
Beedle AM; Turner AJ; Saito Y; Lueck JD; Foltz SJ; Fortunato MJ; Nienaber PM; Campbell KP
J Clin Invest; 2012 Sep; 122(9):3330-42. PubMed ID: 22922256
[TBL] [Abstract][Full Text] [Related]
10. TRAPPC11 and GOSR2 mutations associate with hypoglycosylation of α-dystroglycan and muscular dystrophy.
Larson AA; Baker PR; Milev MP; Press CA; Sokol RJ; Cox MO; Lekostaj JK; Stence AA; Bossler AD; Mueller JM; Prematilake K; Tadjo TF; Williams CA; Sacher M; Moore SA
Skelet Muscle; 2018 May; 8(1):17. PubMed ID: 29855340
[TBL] [Abstract][Full Text] [Related]
11. Ectopic clustering of Cajal-Retzius and subplate cells is an initial pathological feature in Pomgnt2-knockout mice, a model of dystroglycanopathy.
Nakagawa N; Yagi H; Kato K; Takematsu H; Oka S
Sci Rep; 2015 Jun; 5():11163. PubMed ID: 26060116
[TBL] [Abstract][Full Text] [Related]
12. Dystroglycan: a possible mediator for reducing congenital muscular dystrophy?
Sciandra F; Gawlik KI; Brancaccio A; Durbeej M
Trends Biotechnol; 2007 Jun; 25(6):262-8. PubMed ID: 17416431
[TBL] [Abstract][Full Text] [Related]
13. [Pathomechanism and therapeutic strategy of Fukuyama congenital muscular dystrophy and related disorders].
Toda T
Rinsho Shinkeigaku; 2009 Nov; 49(11):859-62. PubMed ID: 20030231
[TBL] [Abstract][Full Text] [Related]
14. The Muscular Dystrophy Gene TMEM5 Encodes a Ribitol β1,4-Xylosyltransferase Required for the Functional Glycosylation of Dystroglycan.
Manya H; Yamaguchi Y; Kanagawa M; Kobayashi K; Tajiri M; Akasaka-Manya K; Kawakami H; Mizuno M; Wada Y; Toda T; Endo T
J Biol Chem; 2016 Nov; 291(47):24618-24627. PubMed ID: 27733679
[TBL] [Abstract][Full Text] [Related]
15. Hypoglycosylation of dystroglycan due to T192M mutation: a molecular insight behind the fact.
Bhattacharya S; Das A; Ghosh S; Dasgupta R; Bagchi A
Gene; 2014 Mar; 537(1):108-14. PubMed ID: 24361964
[TBL] [Abstract][Full Text] [Related]
16. [Recent Advances in α-dystroglycanopathy].
Kuga A; Kanagawa M; Toda T
Brain Nerve; 2011 Nov; 63(11):1189-95. PubMed ID: 22068471
[TBL] [Abstract][Full Text] [Related]
17. Exclusion of WWP1 mutations in a cohort of dystroglycanopathy patients.
Godfrey C; Clement E; Abbs S; Muntoni F
Muscle Nerve; 2011 Sep; 44(3):388-92. PubMed ID: 21996799
[TBL] [Abstract][Full Text] [Related]
18. The many roles of dystroglycan in nervous system development and function: Dystroglycan and neural circuit development: Dystroglycan and neural circuit development.
Jahncke JN; Wright KM
Dev Dyn; 2023 Jan; 252(1):61-80. PubMed ID: 35770940
[TBL] [Abstract][Full Text] [Related]
19. AAV-mediated transfer of FKRP shows therapeutic efficacy in a murine model but requires control of gene expression.
Gicquel E; Maizonnier N; Foltz SJ; Martin WJ; Bourg N; Svinartchouk F; Charton K; Beedle AM; Richard I
Hum Mol Genet; 2017 May; 26(10):1952-1965. PubMed ID: 28334834
[TBL] [Abstract][Full Text] [Related]
20. Mobility shift of beta-dystroglycan as a marker of
Sarkozy A; Torelli S; Mein R; Henderson M; Phadke R; Feng L; Sewry C; Ala P; Yau M; Bertoli M; Willis T; Hammans S; Manzur A; Sframeli M; Norwood F; Rakowicz W; Radunovic A; Vaidya SS; Parton M; Walker M; Marino S; Offiah C; Farrugia ME; Mamutse G; Marini-Bettolo C; Wraige E; Beeson D; Lochmüller H; Straub V; Bushby K; Barresi R; Muntoni F
J Neurol Neurosurg Psychiatry; 2018 Jul; 89(7):762-768. PubMed ID: 29437916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
